Response assessment in Waldenström macroglobulinaemia: Update from the VIth International Workshop

British Journal of Haematology

Volumn 160, Issue 2, 2013, Pages 171-176

  Owen, Roger G ^a   Kyle, Robert A ^b   Stone, Marvin J ^c   Rawstron, Andy C ^a   Leblond, Veronique ^d   Merlini, Giampaolo ^e   Garcia Sanz, Ramon ^f   Ocio, Enrique M ^f   Morra, Enrica ^g   Morel, Pierre ^h   Anderson, Kenneth C ⁱ   Patterson, Christopher J ⁱ   Munshi, Nikhil C ⁱ   Tedeschi, Alessandra ^g   Joshua, Douglas E ^j   Kastritis, Efstathios ^k   Terpos, Evangelos ^k   Ghobrial, Irene M ⁱ   Leleu, Xavier ^l   Gertz, Morie A ^b   Ansell, Stephen M ^b   Morice, William G ^b   Kimby, Eva ^m   Treon, Steven P ⁱ   more..

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e UNIVERSITY OF PAVIA   (Italy)

^f HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^g OSPEDALE NIGUARDA CA GRANDA   (Italy)

^h Hospitalier Schaffner   (France)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

^j ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^k UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^l LILLE UNIVERSITY HOSPITAL   (France)

^m KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

Residual disease; Trials; Waldenstr m macroglobulinaemia

Indexed keywords

BORTEZOMIB; EVEROLIMUS; FLUDARABINE; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOGLOBULIN M; M PROTEIN; MONOCLONAL ANTIBODY; PURINE DERIVATIVE; RAPAMYCIN; RITUXIMAB;

ARTICLE; BONE MARROW EXAMINATION; CAUSE SPECIFIC SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; COMPUTER ASSISTED TOMOGRAPHY; DENSITOMETRY; DISEASE FREE SURVIVAL; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MINIMAL RESIDUAL DISEASE; NEPHELOMETRY; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RELAPSE; TREATMENT RESPONSE; WALDENSTROEM MACROGLOBULINEMIA;

ANTIBODIES, MONOCLONAL; ANTIMETABOLITES; BONE MARROW EXAMINATION; BORONIC ACIDS; DENSITOMETRY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FORECASTING; HEMATOPOIESIS; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENTS; NEOPLASM, RESIDUAL; NEPHELOMETRY AND TURBIDIMETRY; POSITRON-EMISSION TOMOGRAPHY; PYRAZINES; REMISSION INDUCTION; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; WALDENSTROM MACROGLOBULINEMIA;

EID: 84872264088     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12102     Document Type: Article

References (35)

1. Banwait, R., O'Regan, K., Campigotto, F., Harris, B., Yarar, D., Bagshaw, M., Leleu, X., Leduc, R., Ramaiya, N., Weller, E. & Ghobrial, I.M. (2011) The role of 18F-FDG PET/CT imaging in Waldenstrom macroglobulinemia. American Journal of Hematology, 86, 567-572.
2. Barakat, F.H., Medeiros, L.J., Wei, E.X., Konoplev, S., Lin, P. & Jorgensen, J.L. (2011) Residual monotypic plasma cells in patients with Waldenstrom macroglobulinemia after therapy. American Journal of Clinical Pathology, 135, 365-373.
3. Chen, C.I., Kouroukis, C.T., White, D., Voralia, M., Stadtmauer, E., Stewart, A.K., Wright, J.J., Powers, J., Walsh, W. & Eisenhauer, E. (2007) Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 25, 1570-1575.
4. Del Giudice, I., Matutes, E., Osuji, N., Parry-Jones, N., Swansbury, J. & Catovsky, D. (2005) Delayed response to fludarabine in lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia. Haematologica, 90, 268-270.
5. García-Sanz, R., Ocio, E., Caballero, A., Magalhães, R.J.P., Alonso, J., López-Anglada, L., Villaescusa, T., Puig, N., Hernández, J.M., Fernández-Calvo, J., Aguilar, A., Martín, A., López, R., Paiva, B., Orfao, A., Vidriales, B., San-Miguel, J.F. & Del Carpio, D. (2011) Post-treatment bone marrow residual disease >5% by flow cytometry is highly predictive of short progression-free and overall survival in patients with Waldenström's macroglobulinemia. Clinical Lymphoma, Myeloma & Leukemia, 11, 168-171.
6. Gertz, M.A., Abonour, R., Heffner, L.T., Greipp, P.R., Uno, H. & Rajkumar, S.V. (2009) Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial. British Journal of Haematology, 147, 677-680.
7. Hallek, M., Cheson, B.D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Döhner, H., Hillmen, P., Keating, M.J., Montserrat, E., Rai, K.R. & Kipps, T.J. (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood, 111, 5446-5456.
8. Itzykson, R., Le Garff-Tavernier, M., Katsahian, S., Diemert, M.-C., Musset, L. & Leblond, V. (2008) Serum-free light chain elevation is associated with a shorter time to treatment in Waldenstrom's macroglobulinemia. Haematologica, 93, 793-794.
9. Katzmann, J.A., Snyder, M.R., Rajkumar, S.V., Kyle, R.A., Therneau, T.M., Benson, J.T. & Dispenzieri, A. (2011) Long-term biological variation of serum protein electrophoresis M-spike, urine M-spike, and monoclonal serum free light chain quantification: implications for monitoring monoclonal gammopathies. Clinical Chemistry, 57, 1687-1692.
10. Kimby, E., Treon, S.P., Anagnostopoulos, A., Dimopoulos, M., Garcia-Sanz, R., Gertz, M.A., Johnson, S., LeBlond, V., Fermand, J.-P., Maloney, D.G., Merlini, G., Morel, P., Morra, E., Nichols, G., Ocio, E.M., Owen, R., Stone, M. & Bladé, J. (2006) Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. Clinical Lymphoma & Myeloma, 6, 380-383.
11. Laszlo, D., Andreola, G., Rigacci, L., Fabbri, A., Rabascio, C., Mancuso, P., Pruneri, G., Radice, D., Pinto, A., Frigeri, F., Calabrese, L., Billio, A., Bertolini, F. & Martinelli, G. (2010) Rituximab and subcutaneous 2-chloro-2′-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 28, 2233-2238.
12. Leleu, X., Moreau, A.-S., Weller, E., Roccaro, A.M., Coiteux, V., Manning, R., Nelson, M., Leduc, R., Robu, D., Dupire, S., Hatjiharissi, E., Burwick, N., Darre, S., Hennache, B., Treon, S.P., Facon, T., Gertz, M.A. & Ghobrial, I.M. (2008) Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia. Leukemia & Lymphoma, 49, 1104-1107.
13. Leleu, X., Xie, W., Bagshaw, M., Banwait, R., Leduc, R., Roper, N., Weller, E. & Ghobrial, I.M. (2011a) The role of serum immunoglobulin free light chain in response and progression in Waldenstrom macroglobulinemia. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 17, 3013-3018.
14. Leleu, X., Koulieris, E., Maltezas, D., Itzykson, R., Xie, W., Manier, S., Dulery, R., Boyle, E., Gauthier, J., Poulain, S., Tatiana, T., Panayiotidis, P., Bradwell, A.R., Harding, S., Leblond, V., Kyrtsonis, M.-C. & Ghobrial, I.M. (2011b) Novel M-component based biomarkers in Waldenström's macroglobulinemia. Clinical Lymphoma, Myeloma & Leukemia, 11, 164-167.
15. Manier, S., Lejeune, J., Musset, L., Boyle, E., Dulery, R., Debarri, H., Faucompret, J.-L., Gauthier, J., Bories, C., Fouquet, G., Herbaux, C., Tricot, S., Pietrantuono, A., Combat, F., Poulain, S., Harding, S., Leblond, V. & Leleu, X. (2011) Hevylite, a novel M-component based biomarkers of response to therapy and survival in Waldenstrom macroglobulinemia. Blood (ASH Annual Meeting Abstracts), 118, 2667.
16. Moreton, P., Kennedy, B., Lucas, G., Leach, M., Rassam, S.M.B., Haynes, A., Tighe, J., Oscier, D., Fegan, C., Rawstron, A. & Hillmen, P. (2005) Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 23, 2971-2979.
17. Morice, W.G., Chen, D., Kurtin, P.J., Hanson, C.A. & McPhail, E.D. (2009) Novel immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with Waldenström's macroglobulinemia. Modern pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc, 22, 807-816.
18. Murray, D.L., Ryu, E., Snyder, M.R. & Katzmann, J.A. (2009) Quantitation of serum monoclonal proteins: relationship between agarose gel electrophoresis and immunonephelometry. Clinical Chemistry, 55, 1523-1529.
19. Owen, R.G., Barrans, S.L., Richards, S.J., O'Connor, S.J., Child, J.A., Parapia, L.A., Morgan, G.J. & Jack, A.S. (2001) Waldenström macroglobulinemia. Development of diagnostic criteria and identification of prognostic factors. American Journal of Clinical Pathology, 116, 420-428.
20. Owen, R.G., Treon, S.P., Al-Katib, A., Fonseca, R., Greipp, P.R., McMaster, M.L., Morra, E., Pangalis, G.A., San Miguel, J.F., Branagan, A.R. & Dimopoulos, M.A. (2003) Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Seminars in Oncology, 30, 110-115.
21. Paiva, B., Vidriales, M.-B., Cerveró, J., Mateo, G., Pérez, J.J., Montalbán, M.A., Sureda, A., Montejano, L., Gutiérrez, N.C., García de Coca, A., de Las Heras, N., Mateos, M.V., López-Berges, M.C., García-Boyero, R., Galende, J., Hernández, J., Palomera, L., Carrera, D., Martinez, R., de la Rubia, J., Martin, A., Blade, J., Lahuerta, J.J., Orfao, A. & San Miguel, J.F. (2008) Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood, 112, 4017-4023.
22. Pasricha, S.-R., Juneja, S.K., Westerman, D.A. & Came, N.A. (2011) Bone-marrow plasma cell burden correlates with IgM paraprotein concentration in Waldenstrom macroglobulinaemia. Journal of Clinical Pathology, 64, 520-523.
23. Rajkumar, S.V., Harousseau, J.-L., Durie, B., Anderson, K.C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., Jagannath, S., Facon, T., Avet-Loiseau, H., Lonial, S., Palumbo, A., Zonder, J., Ludwig, H., Vesole, D., Sezer, O., Munshi, N.C. & San Miguel, J. (2011) Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood, 117, 4691-4695.
24. Rawstron, A.C., Davies, F.E., DasGupta, R., Ashcroft, A.J., Patmore, R., Drayson, M.T., Owen, R.G., Jack, A.S., Child, J.A. & Morgan, G.J. (2002) Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood, 100, 3095-3100.
25. Riches, P.G., Sheldon, J., Smith, A.M. & Hobbs, J.R. (1991) Overestimation of monoclonal immunoglobulin by immunochemical methods. Annals of clinical biochemistry, 28(Pt 3) 253-259.
26. Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J. & Vardiman, J.W. (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC, Lyon, France.
27. Tedeschi, A., Benevolo, G., Varettoni, M., Battista, M.L., Zinzani, P.L., Visco, C., Meneghini, V., Pioltelli, P., Sacchi, S., Ricci, F., Nichelatti, M., Zaja, F., Lazzarino, M., Vitolo, U. & Morra, E. (2012) Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease. Cancer, 118, 434-443.
28. Treon, S.P., Agus, T.B., Link, B., Rodrigues, G., Molina, A., Lacy, M.Q., Fisher, D.C., Emmanouilides, C., Richards, A.I., Clark, B., Lucas, M.S., Schlossman, R., Schenkein, D., Lin, B., Kimby, E., Anderson, K.C. & Byrd, J.C. (2001) CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia. Journal of Immunotherapy (Hagerstown, Md.: 1997), 24, 272-279.
29. Treon, S.P., Hunter, Z.R., Matous, J., Joyce, R.M., Mannion, B., Advani, R., Cook, D., Songer, J., Hill, J., Kaden, B.R., Sharon, D., Steiss, R., Leleu, X., Branagan, A.R. & Badros, A. (2007) Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 13, 3320-3325.
30. Treon, S.P., Ioakimidis, L., Soumerai, J.D., Patterson, C.J., Sheehy, P., Nelson, M., Willen, M., Matous, J., Mattern, J., 2nd, Diener, J.G., Keogh, G.P., Myers, T.J., Boral, A., Birner, A., Esseltine, D.L. & Ghobrial, I.M. (2009) Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 27, 3830-3835.
31. Treon, S.P., Tripsas, C.K., Ioakimidis, L., Warren, D., Patterson, C., Heffner, L., Eradat, H., Gregory, S.A., Thomas, S., Advani, R., Baz, R., Badros, A.Z., Matous, J., Anderson, K.C. & Ghobrial, I.M. (2011a) Prospective, multicenter study of the MTOR inhibitor everolimus (RAD001) as primary therapy in Waldenstrom's macroglobulinemia. Blood (ASH Annual Meeting Abstracts), 118, 2951.
32. Treon, S.P., Yang, G., Hanzis, C., Ioakimidis, L., Verselis, S.J., Fox, E.A., Xu, L., Hunter, Z.R., Tseng, H., Manning, R.J., Patterson, C.J., Sheehy, P. & Turnbull, B. (2011b) Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia. British Journal of Haematology, 154, 223-228.
33. Tripsas, C., Ioakimidis, L.I., Hunter, Z.R., Patterson, C.J., Manning, R.J., Sheehy, P.S., Turnbull, B. & Treon, S.P. (2012) Comparative response assessment by total serum IgM and IgM M-component in Waldenstrom's macroglobulinemia. Journal of Clinical Oncology, 30, e18575.
34. Varghese, A.M., Rawstron, A.C., Ashcroft, A.J., Moreton, P. & Owen, R.G. (2009) Assessment of bone marrow response in Waldenström's macroglobulinemia. Clinical Lymphoma & Myeloma, 9, 53-55.
35. Weber, D., Treon, S.P., Emmanouilides, C., Branagan, A.R., Byrd, J.C., Bladé, J. & Kimby, E. (2003) Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Seminars in Oncology, 30, 127-131.